News

In November 2016, the FDA granted ADCETRIS Breakthrough Therapy Designation (BTD) for the treatment of patients with CD30-expressing mycosis fungoides and primary cutaneous anaplastic large cell lymphoma who

CA4P is Mateon’s investigational drug, as well as potent and tubulin-binding vascular disrupting agent (VDA). Focus study is assessing CA4P in combination with bevacizumab and physician's choice chemotherapy

Working with well-established and recognized brands in Russia including Lactacyd, Aflubin and Paranit, the firm focuses on a targeted portfolio of over-the-counter drugs in categories such as women’s

The Principal Investigator is Dr. James D. Blanchard, Principal Scientist, Preclinical Development at Aradigm. Professor Luiz Bermudez at Oregon State University, Corvallis, will lead the laboratory research as

Multikine (Leukocyte Interleukin Injection) is being investigated as a potential first-line immunotherapy. Its objective is to harness the immune system of the patient to produce an anti-tumor response.

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, which is designed to uniquely tackle the body’s own immune system to help restore anti-tumor immune response. The combination,

The trial dubbed as OPH1004 had investigated the superiority of Fovista in combination with Eylea (aflibercept) or Avastin (bevacizumab) anti-VEGF therapy over Eylea or Avastin monotherapy. It was

Other partners include the Cell and Gene Therapy Catapult, Stratophase and Synthace, and the collaboration is co-funded by Innovate UK. The aim of the collaboration is to explore

Manufactured by the Florida-based PharmaTech, the liquid drug or dietary supplement products were distributed by Leader Brand, Major Pharmaceuticals and Rugby Laboratories. The distributors have all issued voluntary